期刊文献+

上皮性卵巢癌组织中P73基因的表达及临床意义 被引量:2

下载PDF
导出
摘要 目的:探讨上皮性卵巢癌中P73基因的表达和临床病理特征的关系,为卵巢癌的临床诊断及开展基因治疗提供实验依据。方法:采用EliVision plus免疫组化研究40例上皮性卵巢癌组织、15例正常卵巢组织、25例良性上皮性卵巢肿瘤组织中P73基因的表达。结果:P73基因在正常卵巢组织中阳性率为20%(3/15),在良性上皮性卵巢肿瘤中阳性率为24%(6/25),与上皮性卵巢癌中P73基因表达阳性率[80%(32/40)]比较差异有显著性(P<0.05);随着上皮性卵巢癌病理学分级及临床分期增高,P73基因表达率增高(P<0.05);但不同病理类型之间P73基因表达差异无显著性。结论:P73基因表达与上皮性卵巢癌的发生、发展及组织分化程度有关。P73基因在上皮性卵巢癌组织中表达增强,并随恶性程度增高而增强。
出处 《实用临床医学(江西)》 CAS 2007年第5期9-10,13,共3页 Practical Clinical Medicine
  • 相关文献

参考文献8

  • 1Shimizu M,Saitohy,Itoh H.Immunohisto Chemical Staining of Ha-ras Oncogene Product in Normal,Benign,and Mail Gnant Human Pancrcatc Tissue[J].Hum Pathol,1990,21(6):607-612.
  • 2张秋实,其木格,李继俊.子宫内膜癌p16基因突变及蛋白表达异常的分子学探讨[J].实用肿瘤杂志,2002,17(6):382-385. 被引量:5
  • 3Kaghad M,Bonnet H,Yang A,et al.Monoallelically Exepress Gene Related To p53 at Ip36,a Region Frequeutly Deleted in Neuroblastoma and other Human Cancers[J].Cell,1997,90(4):809.
  • 4Dicer G,Felix F,Iris S,et al.Classification of Asymptomatic Adnexal Masses by Ultrasound,Magnetic Resonance Imaging,and Positron Emission Tomogt Pby[J].Gynecologic Oncology,2000,77:454-459.
  • 5Kahak M.Monocallelically Expressioned in Neuroblastoma and other Human Ip36 a Region Frequently Deleted in Neuroblastoma and other Human Cancer[J].Cell,1997,90:809.
  • 6陈黎明,赵悦,郑冬梅.卵巢癌中野生型p73基因的表达水平的研究[J].中国优生与遗传杂志,2002,10(4):26-27. 被引量:5
  • 7Chen C L,Ip S M,Cheng D,et al.P73 Gene Expression in Ovarian Cancer Tissues and Cell Lines[J].Clin Cancer Res,2000,6(10):3910.
  • 8Ng S W,Yiu G K,Liu Y,et al.Analysis of p73 in Human Borderline and Invasive Ovariantumor[J].Oncogene,2000,19(15):1885.

二级参考文献12

  • 1萨姆布鲁克J 弗里奇EF.分子克隆实验指南(第二版)[M].北京:科学出版社,1992..
  • 2[1]Igaki H, Saki H, Kishi T, et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines [J]. Bioche Biophys Res Commun, 1994,203(2):1090-1095.
  • 3[2]Shimizu M, Saitch Y, Itoh H. Immunohistochemical staining of Ha-ras oncology product in normal, benign and malignant human pancreatic tissues [J]. Hum Pathol,1990,21(6):607-612.
  • 4[3]Max J. New tumor suppressor may rival p53 [J]. Science, 1994,264(5157):344-345.
  • 5[4]Wong YF, Chung TK, Cheung TH, et al. p16INK4 and p15INK4B alterations in primary gynecologic malignancy [J]. Gynecol Oncol,1997,65(2):319-324.
  • 6[5]Peiffer SL, Bbartsch D, Welan AJ, et al. Low frequency of CDKN2 mutation in endometrial carcinoma [J]. Mol Carcinog, 1995,13(4):210-212.
  • 7[6]Shiozawa T, Nikaido T, Shimizu M, et al. Immunohistochemical analysis of the expression of the expression of cdk4 and p16ink4 in human endometrioid-type endometrial carcinoma [J]. Cancer,1997,80(12):2250-2254.
  • 8[7]Mccluskcy LL, Chen C, Delgadillo E, et al. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors [J]. Gynecol Oncol, 1999,72(1):87-92.
  • 9[8]Muscarella P, Melvin WS, Fisher WF, et al. Genetic alteration in gastrinomas and nonfunctioning pancreatic neuroendocrine tumor:an analysis of p16/MTS1 tumor suppressor gene inactivation [J]. Cancer Res, 1998,58(2):237-240.
  • 10[9]Okamoto A, Demeteick DJ, Spillare EA, ct al. Mutations and altered expression of p16INK4 in human cancer [J]. PNAS, 1994,91(23):11045-11049.

共引文献7

同被引文献9

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部